Skip header and navigation

Refine By

4 records – page 1 of 1.

Component-resolved in vitro diagnosis of hazelnut allergy in Europe.

https://arctichealth.org/en/permalink/ahliterature151698
Source
J Allergy Clin Immunol. 2009 May;123(5):1134-41, 1141.e1-3
Publication Type
Article
Date
May-2009
Author
Kirsten Skamstrup Hansen
Barbara K Ballmer-Weber
Joaquin Sastre
Jonas Lidholm
Kerstin Andersson
Hubert Oberhofer
Magdalena Lluch-Bernal
Jonas Ostling
Lars Mattsson
Frauke Schocker
Stefan Vieths
Lars K Poulsen
Author Affiliation
Allergy Clinic, National University Hospital, Copenhagen, Denmark. ksh@dadlnet.dk
Source
J Allergy Clin Immunol. 2009 May;123(5):1134-41, 1141.e1-3
Date
May-2009
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Allergens - diagnostic use - genetics - immunology
Anaphylaxis - diagnosis - immunology
Corylus - immunology
Denmark
Female
Humans
Immunoglobulin E - blood
Male
Middle Aged
Nut Hypersensitivity - diagnosis - immunology
Recombinant Proteins - diagnostic use - genetics - immunology
Rhinitis, Allergic, Seasonal - diagnosis - immunology
Sensitivity and specificity
Spain
Switzerland
Young Adult
Abstract
Food allergy to hazelnut occurs both with and without concomitant pollen allergy.
We sought to evaluate a panel of hazelnut allergens for diagnosis of hazelnut allergy in Spain, Switzerland, and Denmark.
Fifty-two patients with a positive double-blind, placebo-controlled food challenge result with hazelnuts; 5 patients with a history of anaphylaxis; 62 patients with pollen allergy but hazelnut tolerance; and 63 nonatopic control subjects were included. Serum IgE levels to hazelnut extract, recombinant hazelnut allergens (rCor a 1.04, rCor a 2, rCor a 8, rCor a 11), and native allergens (nCor a 9, nCor a Bd8K, nCor a Bd11K) were analyzed by means of ImmunoCAP.
Among patients with hazelnut allergy, 91% (Switzerland/Spain, 100%; Denmark, 75%) had IgE to hazelnut extract, 75% to rCor a 1.04, 42% to rCor a 2, 28% to rCor a 8, and 2% to rCor a 11. The highest rate of sensitization to Cor a 1.04 was found in the northern regions (Switzerland/Denmark, 100%; Spain, 18%), whereas IgE to the lipid transfer protein rCor a 8 prevailed in Spain (Spain, 71%; Switzerland, 15%; Denmark, 5%). IgE to profilin rCor a 2 was equally distributed (40% to 45%). Among control subjects with pollen allergy, 61% had IgE to hazelnut extract, 69% to rCor a 1.04, 34% to rCor a 2, 10% to rCor a 8, and 6% to rCor a 11.
Component-resolved in vitro analyses revealed substantial differences in IgE profiles of hazelnut allergic and hazelnut tolerant patients across Europe.
PubMed ID
19344939 View in PubMed
Less detail

Frequency of atopy in the Arctic in 1987 and 1998.

https://arctichealth.org/en/permalink/ahliterature6713
Source
Lancet. 2002 Aug 31;360(9334):691-2
Publication Type
Article
Date
Aug-31-2002
Author
Tyra Krause
Anders Koch
Jeppe Friborg
Lars K Poulsen
Bjarne Kristensen
Mads Melbye
Author Affiliation
Department of Epidemiology Research, Danish Epidemiology Science Centre, Statens Serum Institut, Copenhagen, Denmark. tgv@ssi.dk
Source
Lancet. 2002 Aug 31;360(9334):691-2
Date
Aug-31-2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Distribution
Age Factors
Aged
Aged, 80 and over
Allergens
Dermatitis, Atopic - blood - epidemiology - etiology
Female
Greenland - epidemiology
Humans
Immunoglobulin E - blood
Male
Mass Screening
Middle Aged
Research Support, Non-U.S. Gov't
Risk factors
Abstract
Few studies have measured the frequency of atopy with objective measures, and most of these studies have been done in industrialised countries. We analysed serum samples from 859 15-80-year-old Greenlanders who had participated in population-based screening campaigns in 1987 and in 1998. We defined atopy as a positive result in an assay that tests for specific IgE against the eight most common inhalant allergens in one pool (grass, birch, mugwort, dog, cat, horse, Cladosporum herbarum, house dust mite). The frequency of atopy doubled between 1987 (39 [10%] of 392) and 1998 (87 [19%] of 467; risk ratio 1.88 [95% CI 1.31-2.68]). This increase was largest in 15-19-year olds, but also occurred in older people, suggesting that the risk factors responsible for the increase in atopy do not operate only in childhood.
PubMed ID
12241878 View in PubMed
Less detail

A prospective, clinical study on asymptomatic sensitisation and development of allergic rhinitis: high negative predictive value of allergological testing.

https://arctichealth.org/en/permalink/ahliterature137341
Source
Int Arch Allergy Immunol. 2011;155(3):289-96
Publication Type
Article
Date
2011
Author
Uffe Bodtger
Kristian Assing
Lars K Poulsen
Author Affiliation
Allergy Clinic, Copenhagen University Hospital, Gentofte, Denmark. uffe.bodtger@dadlnet.dk
Source
Int Arch Allergy Immunol. 2011;155(3):289-96
Date
2011
Language
English
Publication Type
Article
Keywords
Adult
Allergens - diagnostic use - immunology
Betula - immunology
Denmark - epidemiology
Female
Humans
Immunoglobulin E - blood
Incidence
Male
Middle Aged
Poaceae - immunology
Pollen - immunology
Predictive value of tests
Prospective Studies
Rhinitis, Allergic, Seasonal - diagnosis - epidemiology - immunology
Sensitivity and specificity
Skin Tests
Young Adult
Abstract
Asymptomatic aeroallergen sensitisation affects approximately 10% of Western adolescents and is an established risk factor for the development of respiratory allergy. The reported incidence is 2-20% annually. Previous studies are based on out-seasonal symptom recollection or selected populations, conferring bias towards higher incidence rates.
The aim was to determine the incidence of onset of symptoms among clinically well-characterised asymptomatic, sensitised subjects compared with controls, and to evaluate the predictive values of common allergological tests.
We performed a prospective, clinical, non-interventional, 2-year follow-up study on subjects (identified by population screening) with seasonal allergic birch or grass pollen rhinitis (n = 52), asymptomatic sensitisation to grass or birch (AS, n = 52) or non-atopic, healthy control subjects (n = 39). Experimental allergen susceptibility was assessed at inclusion and at follow-up by skin prick test, conjunctival challenge, intradermal late-phase reaction and measurement of specific IgE. Participants completed in-seasonal symptom and medication diaries during 2 subsequent seasons.
We observed an annual incidence rate of 5% for the onset of symptoms in the AS group (healthy control group 0%). At baseline, the AS group displayed intermediate experimental allergen susceptibility. Subjects developing symptoms had higher levels of specific IgE and larger late-phase reaction than those persistently asymptomatic. However, the positive predictive values were low (14-27%) in contrast to the negative predictive values (95-100%).
In a well-characterised young population, asymptomatic aeroallergen sensitisation conferred a low risk for onset of symptoms during the 2-year follow-up. Persistent asymptomatic phenotype could be accurately predicted by negative results from simple allergological testing.
Notes
Comment In: Int Arch Allergy Immunol. 2011;155(3):189-9021293139
PubMed ID
21293149 View in PubMed
Less detail

Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial.

https://arctichealth.org/en/permalink/ahliterature148203
Source
J Allergy Clin Immunol. 2010 Jan;125(1):123-30.e1-3
Publication Type
Article
Date
Jan-2010
Author
Peter Bager
John Arnved
Steen Rønborg
Jan Wohlfahrt
Lars K Poulsen
Tine Westergaard
Henning Willads Petersen
Bjarne Kristensen
Stig Thamsborg
Allan Roepstorff
Christian Kapel
Mads Melbye
Author Affiliation
Statens Serum Institut, Department of Epidemiology Research, Artillerivej 5, DK-2300 Copenhagen, Denmark. pbg@ssi.dk
Source
J Allergy Clin Immunol. 2010 Jan;125(1):123-30.e1-3
Date
Jan-2010
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Animals
Antibodies, Helminth - blood
Denmark
Desensitization, Immunologic
Double-Blind Method
Female
Humans
Immunoglobulin E - blood
Male
Middle Aged
Ovum - immunology
Poaceae - immunology
Pollen - immunology
Rhinitis, Allergic, Seasonal - etiology - immunology - physiopathology - therapy
Treatment Outcome
Trichuris - growth & development - immunology
Young Adult
Abstract
Parasitic helminth infections can protect against allergic airway inflammation in experimental models and have been associated with a reduced risk of atopy and a reduced course of asthma in some observational studies. Although no clinical evidence exists to support the use of helminth therapy for allergic disease, the helminth Trichuris suis has demonstrated efficacy in treatment of inflammatory bowel disease.
To determine efficacy of helminth therapy for allergic rhinitis.
We conducted a double-blind, placebo-controlled, parallel group trial in which 100 subjects age 18 to 65 years with grass pollen-induced allergic rhinitis were randomly assigned to ingest a total of 8 doses with 2500 live T suis ova or placebo with an interval of 21 days. The primary outcome was a change in mean daily total symptom score for runny, itchy, sneezing nose (maximum change, 9.0) or in percentage of well days during the grass pollen season.
Treatment with T suis ova (N = 49) compared with placebo (N = 47) caused transient diarrhea peaking at day 41 in 33% of participants (placebo, 2%), and increased eosinophil counts (P
Notes
Comment In: J Allergy Clin Immunol. 2010 Mar;125(3):766-720153033
Comment In: J Allergy Clin Immunol. 2010 Mar;125(3):767-8; author reply 768-920153034
PubMed ID
19800680 View in PubMed
Less detail